Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Avacta Group PLC LONDON andAvacta Appoints Mats Blom to the Board of Directors as Chair of Audit CommitteeAvacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee.
- Antengene Corporation LimitedAntengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene TherapyAntengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Johnson & JohnsonJohnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerCompanies: Johnson & JohnsonRYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026...
- INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - HIMSThe case alleges Hims & Hers and its top executives made false and/or misleading statements to investors.
- ROSEN, NATIONAL TRIAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- MemoHoney Launch Advanced Brain Memory Support Capsules 2026 in USA: Read Memohoney Supplement Facts, Benefits and Ingredients Highlights.MemoHoney 2026 Announces a natural formula in the USA, designed to support brain health, memory and focus. Explore Memo Honey supplement facts, ingredients and key benefits.
- Zenbody RX Launches Telehealth Platform Built Around Personalized, Clinician-Guided GLP-1 CareThe platform combines online access, individualized treatment, home delivery, and continued patient support in one connected care experience
- Conscientia Health; Red Bank Catholic High SchoolRed Bank Catholic High School and Conscientia Health Open New Wellness Room, Marking Expanded Commitment to Student Mental and Physical HealthRibbon-cutting held on World Suicide Prevention Day — Red Bank Catholic High School officially opened a new Wellness Room on its Broad Street campus today, with a ribbon-cutting and blessing ceremony marking the next chapter of the school's...
- Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancerCompanies: Roche HoldingBasel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer (SCLC) who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor.1 The trial met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001). Tam-Peli also showed robust efficacy across secondary endpoints, significantly extending progression-free survival (PFS) (median PFS 7.4 vs. 2.8 months) and response rates (59.1% vs. 9.7%) compared to standard-of-care topotecan.1
- THE ROSEN LAW FIRM, P. A.HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026...
- HelloNationHVAC Expert Darrin Monks Explains How Dry Air Impacts Indoor Air Quality and Health in Colorado Homes in HelloNationThe article outlines how humidity control and proper HVAC planning support comfort, efficiency, and healthier indoor environments. — How does dry Colorado air affect indoor air quality and overall health inside the home? HelloNation has...
- International Association for the Study of Lung CancerInternational Association for the Study of Lung Cancer Launches Complimentary IASLC Full Membership for Eligible Countries to Expand Worldwide Participation in Thoracic OncologyFull Membership Initiative Removes Financial Barriers for Clinicians, Researchers and Health Professionals in Eligible Low- and Lower-Middle-Income Countries — The International Association for the Study of Lung Cancer (IASLC) today announced the...